SCHEDULE 13G: BlackRock Discloses 5.8% Stake in Day One Biopharmaceuticals
Beneficial Ownership Disclosure
BlackRock, Inc. has reported a 5.8% beneficial ownership stake in Day One Biopharmaceuticals, Inc., holding 5,849,917 shares of common stock.
Summary
- BlackRock, Inc. has filed a Schedule 13G indicating beneficial ownership of 5,849,917 shares of common stock in Day One Biopharmaceuticals, Inc.
- This ownership represents 5.8% of the total outstanding common stock of Day One Biopharmaceuticals, Inc.
- BlackRock, Inc. holds sole voting power over 5,699,831 shares and sole dispositive power over all 5,849,917 shares.
- The filing was made under Rule 13d-1(b), signifying that the shares were acquired in the ordinary course of business and not with the purpose or effect of changing or influencing control of the issuer.
- Various BlackRock business units, including BlackRock Investment Management, LLC, are identified as beneficially owning shares, with some holding 5% or greater of the outstanding shares.
Sentiment
Score: 5
Explanation: The document is a factual regulatory filing disclosing an ownership stake, with no inherent positive or negative sentiment regarding the issuer's performance or outlook.
Positives
- BlackRock, Inc.'s disclosure of a 5.8% stake in Day One Biopharmaceuticals, Inc. may signal institutional confidence in the company's long-term prospects.
Future Outlook
The document does not provide any forward-looking statements or guidance regarding Day One Biopharmaceuticals, Inc.'s future performance or strategic direction.
Industry Context
This Schedule 13G filing is a standard regulatory disclosure required when an institutional investor, such as BlackRock, acquires beneficial ownership of more than 5% of a company's voting class of securities. It indicates a passive investment, meaning BlackRock does not intend to influence or change control of Day One Biopharmaceuticals, Inc. Such filings provide transparency into significant institutional holdings within the market.
Stakeholder Impact
- Shareholders of Day One Biopharmaceuticals, Inc. may view BlackRock's significant stake as a positive indicator of institutional confidence in the company.
Key Dates
| Date | Description |
|---|---|
| 04/30/2023 | Date of previously revoked Power of Attorney for BlackRock, Inc. |
| 01/21/2025 | Date of new Power of Attorney executed by BlackRock, Inc. |
| 06/30/2025 | Date of event which required the filing of this statement. |
| 07/17/2025 | Date the Schedule 13G statement was signed by BlackRock, Inc. |
Keywords
BlackRock, Day One Biopharmaceuticals, Schedule 13G, beneficial ownership, institutional investment, common stock, equity stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.